UST has partnered with ThinkBio.Ai, an AI-powered solutions provider for biopharmaceutical and healthcare organisations.
The partnership aims to empower UST to more efficiently leverage its expertise in digital transformation and advanced solutions to complement ThinkBio.Ai’s AI-powered R&D capabilities. Together, the companies said they are hoping to deliver solutions that accelerate AI transformation journeys and improve outcomes for biopharma and healthcare organizations worldwide.
Leveraging advanced in-house expertise in oncology, immunology, neurology, and cardiology, ThinkBio.Ai has developed a suite of AI-powered solutions to address critical challenges across pharma and biotech preclinical and clinical R&D pipelines. These include data-driven strategies to identify the most optimal treatments, salvaging failed drugs through repurposing or combination therapies, and improving clinical trial success through biomarker-driven patient stratification and digital twin-enabled trial matching.
ThinkBio.Ai’s AI-enhanced Research Co-pilot (R-COP) uses AI to extend the existing Laboratory Information Management System (LIMS) capabilities. Fully interoperable with existing infrastructure, the tool transforms routine processes into dynamic, insight-driven research operations. These solutions are designed to support biopharma companies and healthcare providers in accelerating innovation and improving patient care.
“This partnership will bring our unique AI and knowledge-based transformation products and solutions for Research and Discovery (R&D) to UST’s focus on digital transformation capabilities and building Gen AI solutions for different industries, including the life science sector. Together, we will build custom ecosystems to help clients and partners stay ahead in a well-regulated, dynamic, and competitive landscape,” said Pradeep Palazhi, founder and CEO of ThinkBio.Ai.
“We will integrate ThinkBio.Ai’s AI-powered R&D transformation solutions with UST’s strengths in digital transformation and Gen AI across life sciences – pharma, biotech, and medical devices. This strategic collaboration will drive innovation, accelerate time-to-value, and deliver measurable impact across the research and development value chain for our customers,” said Anu Koshy, life science cluster leader, UST.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
